Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213232 | 0.90 | GAA (0.37) | MAPTGSK3AGSK3BKMT2AMEN1 | |
| SCHEMBL10046750 | 0.86 | GAA (0.39) | MAPTGSK3AGSK3BKMT2AMEN1 | |
| SCHEMBL14213245 | 0.80 | ALDH1A1 (0.42) | MAPTKMT2AMEN1MAPK1TSHR | |
| SCHEMBL14213225 | 0.79 | CYP1A2 (0.52) | MAPTKMT2ATSHRALDH1A1POLB | |
| SCHEMBL16501741 | 0.78 | GAA (0.37) | MAPTGSK3AGSK3BKMT2AMEN1 | |
| SCHEMBL10046742 | 0.71 | ESR1 (0.46) | KMT2AMEN1USP2MAPK1HSD17B10 | |
| SCHEMBL14213236 | 0.70 | TSHR (0.38) | MAPTMAPK1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL15479693 | 0.70 | BCHE (0.43) | KMT2AMAPK1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL10837403 | 0.69 | SMN1; SMN2 (0.61) | MAPTKMT2AMEN1MAPK1ALDH1A1 | |
| SCHEMBL13872639 | 0.69 | HDAC6 (0.47) | MAPTKMT2AMEN1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716343-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-06 | — | — | US | disclosed |
| US-8642656-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | MAPT 4561/4885GSK3A 4592/4885GSK3B 4636/4885 |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | MAPT 4561/4885GSK3A 4592/4885GSK3B 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.